MedPath

The effect of systemic antibiotics on post-surgical complications and patient-centered outcomes in patients undergoing implant surgery with guided bone regeneration and simultaneous sinus floor elevation

Phase 4
Recruiting
Conditions
implant surgery with guided bone regeneration and simultaneous sinus floor elevation
Registration Number
2024-511366-36-00
Lead Sponsor
Medical University Of Graz
Brief Summary

To evaluate the effect of systemic antibiotic administration compared to placebo in patients undergoing oral implant therapy with simultaneous lateral sinus floor elevation and guided bone regeneration (GBR) in regard to patient-centered outcomes.

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing, recruiting
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

Medically healthy adult (ASA classification I-II), age ≥ 21 years old

Non-smoker, previous smoker (quit ≥ 5 years); light smoker with less than 10 cigarettes/ day

Not allergic to Amoxicillin/Penicillin antibiotics, NSAIDS or corn-starch

Edentulous spaces in the posterior maxilla in one or 2 posterior quadrants with an alveolar bone defect requiring sinus floor elevation and allowing implant placement of up to 3 dental implants and simultaneous GBR (residual crest height 3-5 mm; per implant site (Felice et al. 2012; Park et al. 2019).

Absence of signs of pathology of the sinus membrane and acute sinusitis requiring ongoing management

Exclusion Criteria

Medically compromised subjects (ASA classification III-V)

Type 1 implant placement (immediate implant placement following extraction)

Need for simultaneous soft tissue augmentation

Residual bone height of > 5mm.

Subjects aged < 21 years old

General contraindications against implant treatment or augmentative procedures (e.g. immunodeficiency, advanced systemic diseases, corticosteroid medication)

Those taking Bisphosphonates/anti-angiogenic/RANKL inhibitor medications or receiving local radio-therapy

Heavy smoker or previous heavy smoker (quit < 5 years; ≥ 10 cigarettes/day)

Allergic to Amoxicillin or Penicillin antibiotics, NSAIDS and / or corn starch

Use of any form of antibiotics in the last 3 months or subjects requiring regular antibiotic prophylaxis prior to dental treatment

Pregnant or breast feeding. Self-declared intend to conceive (A pregnancy test will be performed for all female patients).

Need for 2 stage sinus augmentation

Acute or unmanaged symptomatic sinusitis

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patient Reported Outcome Measures (PROMs): Visual analogue scores VAS (0-10) on the wound (bleeding, swelling, pain, bruising (haematoma)) and discomfort of the sinuses (nosebleed, nasal congestion, rhinorrhea (excessive nasal discharge including posterior nasal drip), feeling of pressure, hyposmia (reduction in smell)) on days 1-7 & 14 .

Patient Reported Outcome Measures (PROMs): Visual analogue scores VAS (0-10) on the wound (bleeding, swelling, pain, bruising (haematoma)) and discomfort of the sinuses (nosebleed, nasal congestion, rhinorrhea (excessive nasal discharge including posterior nasal drip), feeling of pressure, hyposmia (reduction in smell)) on days 1-7 & 14 .

Secondary Outcome Measures
NameTimeMethod
Clinical recordings of post-surgical complications at week 2, 4, 16-20 and 6 months after crown- installation on: flap closure/dehiscence, pain/sensitivity on palpation, swelling (obliteration of the sulcus), suppuration/purulent discharge, Implant stability (at initial placement and 2nd stage surgery).

Clinical recordings of post-surgical complications at week 2, 4, 16-20 and 6 months after crown- installation on: flap closure/dehiscence, pain/sensitivity on palpation, swelling (obliteration of the sulcus), suppuration/purulent discharge, Implant stability (at initial placement and 2nd stage surgery).

Trial Locations

Locations (1)

Medical University Of Graz

🇦🇹

Graz, Austria

Medical University Of Graz
🇦🇹Graz, Austria
Michael Payer
Site contact
031638580659
mi.payer@medunigraz.at

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.